vimarsana.com

Page 7 - சுவிஸ் கூட்டாட்சியின் அலுவலகம் ஆஃப் பொது ஆரோக்கியம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

NovoCure (NVCR) Q4 2020 Earnings Call Transcript

NovoCure (NVCR) Q4 2020 Earnings Call Transcript Motley Fool Transcribing © The Motley Fool Logo of jester cap with thought bubble. NovoCure (NASDAQ: NVCR) Ladies and gentlemen, thank you for standing by, and welcome to the NovoCure fourth-quarter and full-year 2020 earnings conference call. [Operator instructions] Please be advised that today s conference is being recorded. [Operator instructions] I would now like to hand the conference over to your speaker today, Gabrielle Fernandes, director of investor relations. Thank you. Please go ahead, ma am. Gabrielle Fernandes Director of Investor Relations Good morning, everyone, and thank you for joining us to review NovoCure s fourth-quarter and full-year 2020 performance. I am joined on the phone by our executive chairman, Bill Doyle; our CEO, Asaf Danziger; and our CFO, Ashley Cordova. Other members of our executive leadership team are also on the call and available for Q&A. The slides presented toda

Switzerland Delays AstraZeneca Vaccine Approval, Wanting More Data

Published: Feb 05, 2021 By Gail Dutton Alexanderstock23 / Shutterstock AstraZeneca’s rolling authorization application for its COVID-19 vaccine a few days ago, saying more data is needed “to obtain more information about safety, efficacy, and quality.” AstraZeneca’s Phase III clinical trial of ChAdOx1 nCoV-19 (AZD1222) shows 76% efficacy after the initial dose and 82% efficacy 12 weeks later, after the second dose. Data show it actually increases efficacy by extending the time between doses. The vaccine already is approved by the E.U. and by approximately 40 countries, including the U.K. None-the-less, Swissmedic concluded, “The data submitted and analyzed so far are not yet sufficient to permit authorization.”

Novartis agrees to help Pfizer-BioNTech produce Covid-19 vaccine

Novartis agrees to help Pfizer-BioNTech produce Covid-19 vaccine Novartis is based in Basel Keystone / Georgios Kefalas Swiss pharma giant Novartis says it has signed an initial agreement to provide manufacturing capacity for Pfizer and BioNTech s Covid-19 vaccine. This content was published on January 29, 2021 - 13:14 January 29, 2021 - 13:14 Reuters/Novartis/SWI swissinfo.ch/ilj See in other languages: 3 The move aimed at helping boost production as demand currently outstrips supply. The agreement will see Novartis utilizing its aseptic manufacturing facilities at its site in Stein, Switzerland, Novartis said in a statement on Friday. External link Subject to reaching a final agreement, Novartis plans to commence production in the second quarter of 2021.

Swiss exempt from EU vaccine export controls

Swiss exempt from EU vaccine export controls European Commissioner Valdis Dombrovskis speaks during an online news conference on Friday Copyright 2020 The Associated Press. All Rights Reserved Switzerland is among the countries exempt from the European Union’s vaccine export controls, the European Commission said on Friday. The plan has been drawn up to ensure that the EU has enough supplies of Covid-19 vaccine. This content was published on January 29, 2021 - 18:22 January 29, 2021 - 18:22 Reuters/Keystone-SDA/SWI swissinfo.ch/ilj EU trade commissioner Valdis Dombrovskis told a news conference that the export monitoring and controls were time limited , initially lasting until the end of March, and applied to Covid-19 vaccines the EU had bought in advance.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.